Conditions: Glaucoma
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 15
Healthy volunteers: no

Brief summary:
A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.

Detailed description:

Arms:
arm 1: Combigan® (fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks. arm 2: Cosopt® (fixed combination of dorzolamide hydrochloride - timolol maleate ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.

Interventions: intervention 1: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution intervention 2: fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
Intervention descriptions: intervention 1: 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks intervention 2: 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks

Protocol document: